Puma Biotechnology Grants Inducement Stock Awards to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology has granted 7,000 restricted stock units under its 2017 Employment Inducement Incentive Award Plan to new non-executive employees. The inducement awards align with Nasdaq Listing Rule 5635(c)(4) and aim to attract and retain top talent. The vesting schedule spans three years, with one-third of the shares vesting on the first anniversary of the award date and then one-sixth vesting every six months thereafter, contingent on continued service.

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company focused on innovative cancer care products, has announced the grant of 7,000 restricted stock units (RSUs) to two new non-executive employees. The awards were approved by the Compensation Committee of Puma’s Board of Directors on July 1, 2025, under the company’s 2017 Employment Inducement Incentive Award Plan [1].

The RSUs vest over a three-year period, with one-third of the shares underlying the award vesting on the first anniversary of the award’s vesting commencement date, July 1, 2025, and one-sixth of the shares vesting every six months thereafter, contingent on continued service. The awards are designed to attract and retain top talent, aligning with Nasdaq Listing Rule 5635(c)(4) [1].

Puma Biotechnology’s latest move underscores its commitment to fostering a skilled workforce and ensuring long-term success in the competitive biopharmaceutical industry. The company has been actively involved in developing and commercializing innovative cancer treatments, including the oral drug neratinib, marketed as NERLYNX®, which has received FDA approval for various indications [1].

References:
[1] https://www.businesswire.com/news/home/20250702179212/en/Puma-Biotechnology-Reports-Inducement-Awards-Under-Nasdaq-Listing-Rule-5635c4